Ausun Pharm(SH:603229) Ge Long Hui A P P·2025-09-16 08:22Core Viewpoint - Aoxiang Pharmaceutical (603229.SH) announced that its wholly-owned subsidiary, Zhejiang Qizheng Pharmaceutical Co., Ltd., received the drug registration certificate for Imatinib Mesylate Tablets from the National Medical Products Administration, marking a significant milestone in the company's product portfolio [1]. Group 1: Product Approval - The drug registration certificate (Certificate No. 2025S02736) for Imatinib Mesylate Tablets has been officially issued [1]. - Imatinib Mesylate Tablets are the world's first targeted molecular therapy for cancer, specifically indicated for patients with chronic myeloid leukemia (CML) in acute or accelerated phases, or those who have failed alpha-interferon treatment [1]. - The drug is also indicated for patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) [1]. Group 2: Mechanism of Action - The active ingredient, Imatinib, is a tyrosine kinase inhibitor that effectively inhibits the Philadelphia chromosome gene, preventing the phosphorylation reaction from being catalyzed and leading to the loss of chromosome function [1]. - This mechanism results in the suppression of abnormal white blood cell proliferation [1]. - Imatinib also binds to the active site of tyrosine kinase, blocking its activity [1].